&lt;p&gt;Radiotherapy of Pulmonary Hepatoid Adenocarcinoma with Intrahepatic Hemangioma: A Case Report&lt;/p&gt;

Wang, Wenting; Li, Guang

doi:10.2147/ott.s275340

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary HAL is mainly differentiated from primary pulmonary adenocarcinoma, lung metastases of hepatocellular carcinoma, lung metastases of hepatoid adenocarcinoma from other sites (such as the stomach, ovary, and uterus), and germ cell tumors, which can also cause an increase in AFP. Although the diagnosis of HAL relies on morphology, we hold that imagological examination and immunohistochemical analysis, including AFP, CK7, hepatocyte, GPC-3, TTF-1, arg-1, and CDX2 staining, are still important for the diagnosis and differential diagnosis of HAL based on our case study and other studies (48). The mechanism of AFP expression in this type of adenocarcinoma may be related to the homology of the lung and liver.…”

Section: Discussionmentioning

confidence: 52%

Hepatoid Adenocarcinoma of the Lung: A Systematic Review of the Literature From 1981 to 2020

et al. 2021

View full text Add to dashboard Cite

ObjectivesWe report the first case of hepatoid adenocarcinoma of the lung (HAL) with PIK3CA mutation. In addition, we analyzed data from HAL cases over the past 40 years to study its main treatment methods, prognosis, and the relationship between prognosis and the serum alpha-fetoprotein (AFP) level before treatment.MethodsWe report a 66-year-old male case who was diagnosed with locally advanced HAL with PIK3CA mutation and carried out a systematic literature search for HAL cases documented between 1981 and 2020. General patient information including case characteristics was extracted and summarized. The median OS (mOS) of HAL patients was determined using the KM survival curve. The Cox proportional hazards regression model was used to evaluate the effect of tumor size, location, and serum AFP value before treatment and radical surgery (RS) on the prognosis of patients.ResultsA total of 46 studies including 51 HAL patients was included in our review. Our study revealed that 52.9% of tumors were located in the upper lobe of the right lung. The proportion of serum AFP-positive patients before treatment, early-stage patients (TNM stage I and II), and patients who had received surgery were 69.2%, 34.1%, and 40%, respectively. The mOS of HAL patients was 16.0 months. The 2-year and 5-year survival rates of the patients were 35.3% and 8.0%, respectively. In the subgroup analysis, the 2-year survival rate for patients who received RS was 62.5%, while for patients who were unable to undergo RS, it was only 12.5% (p = 0.009). The Cox proportional hazards regression model indicated that RS can significantly improve the prognosis of HAL patients (p = 0.011), although the location and size of tumor as well as the serum AFP value before treatment had no significant effect on their prognosis (p = 0.82, p = 0.96, p = 0.25).ConclusionsHAL patients have a poor prognosis, and the survival benefits for patients receiving chemoradiotherapy or chemotherapy alone appear to be limited. We demonstrate statistically for the first time that pretreatment serum AFP values are not related to the prognosis of HAL patients and RS can significantly improve patient prognosis.

show abstract

Section: Discussionmentioning

confidence: 52%

Hepatoid Adenocarcinoma of the Lung: A Systematic Review of the Literature From 1981 to 2020

et al. 2021

View full text Add to dashboard Cite

show abstract

“…At the same time, CT examination and re-examination of serum AFP levels showed that the patient's lung lesions improved and serum AFP levels decreased after four cycles. Wang WT et al 31 reported a HAL patient who received radiation therapy alone. After 50Gy/25 fractions of radiotherapy, the tumor shrank significantly while the patient refused to accept further treatment after the radiotherapy of 60Gy/30f.…”

Section: Treatmentmentioning

confidence: 99%

Hepatoid Adenocarcinoma of the Lung

Fan

2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Hepatoid adenocarcinoma of the lung (HAL) is an comparatively rare malignant tumor originating from the lung with shorter survival. HAL morphologically and pathologically exhibits hepatocellular carcinoma (HCC)-like characteristics, while its clinical features resemble pulmonary adenocarcinoma. High concentration of alpha-fetoprotein (AFP) is often detected in the serum of HAL patients with no hepatic occupying lesion. Patients with AFP-negative HAL survive a few months longer than those with positive AFP test. HAL is a rare type of carcinoma, so there is a lack of systematic and extensive statistical research. The treatment strategy for HAL is similar to common lung adenocarcinoma. Complete surgical resection and adjuvant chemotherapy are the current major treatments for HAL patients. There are also a few of case reports suggesting that HAL patients may benefit from immunotherapy and targeted therapy. This review focuses on the clinical and pathological features, immunohistochemical staining characteristics, treatment and prognosis of HAL.

show abstract

Clinical characteristics of Hepatoid adenocarcinoma of the lung: Four case reports and literature review

Zhuansun

Bian

Zhao

et al. 2021

Cancer Treatment and Research Communications

View full text Add to dashboard Cite

<p>Radiotherapy of Pulmonary Hepatoid Adenocarcinoma with Intrahepatic Hemangioma: A Case Report</p>

Cited by 5 publications

References 25 publications

Hepatoid Adenocarcinoma of the Lung: A Systematic Review of the Literature From 1981 to 2020

Hepatoid Adenocarcinoma of the Lung: A Systematic Review of the Literature From 1981 to 2020

Hepatoid Adenocarcinoma of the Lung

Clinical characteristics of Hepatoid adenocarcinoma of the lung: Four case reports and literature review

Contact Info

Product

Resources

About